scholarly journals CHARACTERIZATION OF THE ONCOGENIC PHENOTYPE IN EXTRANODAL NATURAL KILLER/T‐CELL LYMPHOMA, NASAL TYPE THROUGH GENE EXPRESSION PROFILE. SPANISH LYMPHOMA GROUP GELTAMO

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
E González-Barca ◽  
L Gato ◽  
A Esteve ◽  
R Sanz‐Pamplona ◽  
L Tomás ◽  
...  
Keyword(s):  
Gene Expression ◽  
T Cell ◽  
Natural Killer ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Cell Lymphoma ◽  
Nasal Type ◽  
Natural Killer T Cell ◽  
Killer T Cell

Linfoma de células T/Natural Killer extranodal, tipo nasal

2017 ◽  
Vol 43 (3) ◽  
pp. 216-221
Author(s):  
Jorge Luis Alfredo Herrera Ariza ◽  
Perla Villamor Rojas
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
Nasal Type ◽  
Natural Killer T Cell ◽  
Lethal Midline Granuloma ◽  
Calidad De Vida ◽  
Killer T Cell ◽  
Midline Granuloma ◽  
Natural Killer T

Introducción: El linfoma de células T/Natural Killer (T/NK) extranodal, tipo nasal, es un linfoma extra-ganglionar poco frecuente, con extensión a lo largo de la línea media facial, rápidamente progresivo, catastrófico y de mal pronóstico, por lo que también se le conoce como “granuloma letal de la línea media”. Objetivo: El propósito de este artículo es revisar la literatura disponible y actualizada sobre el linfoma de células T/NK extranodal, tipo nasal: manifestaciones clínicas, estándares de enfoque, diagnóstico, pronóstico y tratamiento. Diseño: Revisión Narrativa de la literatura. Metodología: Revisión de la literatura mediante búsqueda selectiva por términos MeSH: Extranodal Natural Killer /T cell lymphoma, nasal type, lethal midline granuloma, de las bases de datos: MEDLINE, Current Contents, Cochrane, Pubmed y Scielo, entre los años 2000 y 2014. Resultados: Se revisaron 36 artículos según los requerimientos de los objetivos. El linfoma de células T/NK es una neoplasia rápidamente progresiva, destructiva y de mal pronóstico excepto en los casos donde el diagnóstico ha sido oportuno. Conclusiones: El diagnóstico y tratamiento tempranos del linfoma de células T/NK extranodal, tipo nasal, son las únicas herramientas para mejorar el mal pronóstico y gran afectación en la calidad de vida de los pacientes con esta enfermedad.

scholarly journals Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Huiqiang Huang ◽  
Jun Zhu ◽  
Ming Yao ◽  
Tae Min Kim ◽  
Dok Hyun Yoon ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Phase 2 ◽  
Nasal Type ◽  
Natural Killer T Cell ◽  
Phase 2 Study ◽  
Duration Of Response ◽  
Killer T Cell

Abstract Background Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data from the primary analysis of a phase 2 study of daratumumab monotherapy in relapsed or refractory (R/R) NKTCL. Methods This phase 2 study with Simon’s two-stage design evaluated daratumumab in patients with histologically confirmed extranodal NKTCL, nasal type, per WHO classification that was refractory to or relapsed after ≥ 1 line of chemotherapy, who were not candidates for other treatment modalities. All patients received daratumumab 16 mg/kg intravenously once weekly for Cycles 1 and 2, every other week for Cycles 3 through 6, and every 4 weeks thereafter until progression or unacceptable toxicity; all cycles were 28 days. The primary end point was objective response rate (ORR) based on blinded independent central review per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin Lymphoma (Lugano classification). Results In total, 32 Asian patients received daratumumab. The ORR was 25.0% (95% confidence interval [CI] 11.5–43.4); all 8 responders had a partial response; and the median duration of response was 55.0 days (95% CI 29–339). At 10.2 months of median follow-up, median progression-free survival (PFS) was 53.0 days (95% CI 43–106); the 4-month PFS rate was 13.0%. Median overall survival (OS) was 141.0 days (95% CI 94–438); the 6-month OS rate was 42.9%. Nineteen (59.4%) patients had grade 3/4 treatment-emergent adverse events (TEAEs); the most common was thrombocytopenia (25.0%; n = 8). TEAEs leading to death occurred in 4 patients (death, respiratory failure, septic shock, and pneumonia); all were unrelated to daratumumab. Conclusions In patients with R/R NKTCL, daratumumab monotherapy was well tolerated with no new safety concerns and achieved an ORR of 25.0%. However, no patients achieved complete response, and duration of response was short. Trial registration ClinicalTrials.gov, NCT02927925. Registered 7 October 2016.

scholarly journals An Unusual Case of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Masquerading as Dacryocystitis and Sinusitis

2021 ◽  
pp. 014556132098764
Author(s):  
Anthony N. Eze ◽  
Adedoyin O. Kalejaiye
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
Central Nervous System Involvement ◽  
The United States ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Natural Killer T Cell ◽  
Killer T Cell ◽  
Natural Killer T

Extranodal natural killer (NK)/T-cell lymphoma, nasal type (NNKTL) is a rare and highly aggressive non-Hodgkin lymphoma originating from NK or γδ T cells infected by Epstein-Barr virus (EBV). In the United States, NNKTL is usually noted in people of Asian or Hispanic descent. Natural killer/T-cell lymphoma, nasal type commonly involves the upper aerodigestive tract, including the nasopharynx, nasal cavity, Waldeyer’s ring, and oropharynx. Extensive local destruction and invasion has been noted, especially of the paranasal sinuses, hard palate, and central nervous system; involvement of the nasolacrimal duct with dacryocystitis is yet to be reported. We report a rare case of a Hispanic man with extranodal NNKTL masquerading as persistent dacryocystitis and necrotizing sinusitis unresponsive to antibiotics and surgical intervention. An extensive background of necrosis and inflammation was noted on pathology, and additional analysis with immunohistochemistry and in situ hybridization after repeat biopsy were necessary for accurate diagnosis.

scholarly journals Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type

2016 ◽  
Vol 12 (2) ◽  
pp. 825-836 ◽  
Author(s):  
Hua Wang ◽  
Pengfei Li ◽  
Xinke Zhang ◽  
Zhongjun Xia ◽  
Yue Lu ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Vascular Invasion ◽  
Cell Lymphoma ◽  
Prognostic Indicator ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Natural Killer T Cell ◽  
Killer T Cell ◽  
Natural Killer T

Laryngeal Extranodal Nasal-type Natural Killer/T-cell Lymphoma

2019 ◽  
Vol 43 (7) ◽  
pp. 995-1004
Author(s):  
Chun-xiang Xiang ◽  
Zi-hang Chen ◽  
Sha Zhao ◽  
Li-min Gao ◽  
Qing Tao ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Natural Killer T Cell ◽  
Killer T Cell ◽  
Natural Killer T
Sign in / Sign up

Export Citation Format

Share Document